Bioxyne Ltd (Bioxyne) manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative novel medicines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Bioxyne's R&D strategy is centered on innovation and expansion within the health and wellness sector. The company focuses on developing efficacious health products by extending into new dose formats and active ingredients. Since acquiring Breathe Life Sciences in 2023, Bioxyne has maintained its core value of clinical research excellence, enhancing its delivery through strategic advancements. In 2025, Bioxyne marked a significant milestone by expanding its operations into pharmaceutical and health product manufacturing in Australia, following the acquisition of a GMP license from the TGA in February 2024. This development has enabled the company to rapidly scale its manufacturing capabilities, laying the groundwork for further expansion into international markets such as Germany, the UK, and Europe. The company's R&D efforts are supported by a robust infrastructure that includes contract manufacturing of final dose form products, active pharmaceutical ingredients, and novel foods. Bioxyne is committed to leveraging its expertise in medicinal cannabis, probiotics, and functional mushrooms to meet the growing demand for innovative health solutions. In FY2025, the company spent AUD0.2 million on its R&D activities, which as a percentage of revenue stood at 0.6%.